No increased cancer risk in patients with rheumatic diseases and prior malignancy treated with novel therapies

A cohort study revealed that cancer risk in patients with rheumatic diseases and a history of previous malignancy did not differ significantly based on the type of biological disease-modifying antirheumatic drugs (DMARDs) and targeted synthetic DMARDs exposure. Besides, there was no difference between those under anti-TNF therapy versus other DMARDs.    More and more patients with rheumatic diseases are treated with novel therapies, including biological and targeted synthetic DMARDs. Though these patients generally have a higher prevalence of comorbidities, including cancer, available robust data on the malignancy risk is limited. A cohort study including 352 patients investigated the occurrence and relative risk of incident cancer in those with rheumatic diseases and prior malignancy treated with DMARDs [1]. The study selected patients from the multicentre, prospective Spanish BIOBADASER registry (

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 1 December, 20221 December, 2022